Innate Pharma SA Interest Expense Income Net Defined Benefit Liability Asset
Innate Pharma SA (IPHYF) reported Interest Expense Income Net Defined Benefit Liability Asset of -EUR 27.00 thousand for the 12-month period ending 2023-12-31, per its 20-F filed 2024-04-04.
Discontinued › Expense Statement
ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset · last filed 2024-04-04
| Period end | Interest Expense Income Net Defined Benefit Liability Asset 6 month | Interest Expense Income Net Defined Benefit Liability Asset 12 month |
|---|---|---|
| 2023-12-31 | -27.00K EUR 20-F · filed 2024-04-04 | |
| 2023-06-30 | -17.00K EUR 6-K · filed 2023-09-14 | |
| 2022-12-31 | -62.00K EUR 20-F · filed 2024-04-04 | |
| 2022-06-30 | -14.00K EUR 6-K · filed 2022-09-15 | |
| 2021-12-31 | -47.00K EUR 20-F · filed 2024-04-04 | |
| 2021-06-30 | -22.00K EUR 6-K · filed 2021-09-15 | |
| 2020-12-31 | -35.00K EUR 20-F · filed 2023-04-06 | |
| 2019-12-31 | 55.00K EUR 20-F · filed 2022-04-04 | |
| 2018-12-31 | 43.00K EUR 20-F · filed 2021-04-27 | |
| 2017-12-31 | 36.00K EUR 20-F · filed 2020-04-24 |